GlassScriptPhysician profile
Jerry Kulangara John
NPI 1285377457
$9,358.01
in general payments reported to CMS, 2019-2025
25 companies · $3,997 in 2025
The $3,997 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $20.98 · 2023: $2,001 · 2024: $3,339 · 2025: $3,997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,024 · Education: $313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,023.75 |
| Education | $313.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,081.09 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,066.95 | 2023-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $1,048.40 | 2022-2025 | Winlevi, Absorica Ld, Ilumya |
| Pfizer INC. | $955.40 | 2023-2025 | |
| Abbvie INC. | $864.79 | 2023-2025 | |
| Incyte Corporation | $746.71 | 2023-2025 | Opzelura, Opzelura |
| Galderma Laboratories, L.P. | $745.01 | 2023-2025 | Nemluvio, Aklief, Oracea |
| Ucb, INC. | $469.33 | 2023-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $401.34 | 2023-2024 | Sotyktu |
| Lilly USA, LLC | $382.00 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $325.08 | 2023-2025 | |
| Leo Pharma INC. | $312.89 | 2023-2025 | Adbry, Anzupgo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $222.38 | 2024-2025 | Spevigo |
| Strata Skin Sciences, INC. | $150.49 | 2024 | Xtrac |
| Amgen INC. | $127.72 | 2024-2025 | Otezla, Otezla |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $106.51 | 2023-2025 | Zoryve |
| Almirall LLC | $88.61 | 2025 | Seysara, Klisyri |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $51.48 | 2023-2025 | Targretin, Cabtreo |
| Biofrontera INC. | $47.19 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Mayne Pharma Commercial LLC | $45.26 | 2024 | |
| Journey Medical Corporation | $41.85 | 2024-2025 | |
| Blueprint Medicines Corporation | $26.47 | 2025 | Ayvakit |
| Fidia Pharma USA INC. | $20.15 | 2025 | |
| Verrica Pharmaceuticals INC. | $17.40 | 2024 | Ycanth |
| Organon LLC | $13.51 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.